Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

23.10.2019 | short review | Ausgabe 4/2019 Open Access

memo - Magazine of European Medical Oncology 4/2019

Neoadjuvant therapy in urothelial cancer

New therapies on the horizon

memo - Magazine of European Medical Oncology > Ausgabe 4/2019
Stephan Brönimann, David D’Andrea, Shahrokh F. Shariat, MD Kilian M. Gust
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Neoadjuvant cisplatin-based chemotherapy is standard treatment for muscle-invasive bladder cancer before radical cystectomy (RC). Despite level 1 evidence demonstrating an overall survival benefit for patients undergoing RC after neoadjuvant chemotherapy (NAC), acceptance rates are still low. In high-risk upper tract urothelial cancer (UTUC), cumulative evidence suggests that NAC for locally advanced UTUC can improve oncological outcome. Ongoing phase 3 trials will finally prove the benefit or futility of NAC in this tumor entity. Since urothelial cancer (UC) is a heterogeneous disease, predictive biomarkers are needed to select specific patient populations and potentially increase response rates to NAC. Novel targeting therapies, including immune checkpoint inhibitors, have been approved for metastatic UC. In combination with predictive biomarkers, these might have the potential to change systemic therapy for UC from a “one-fits-all” principle to a more individualized approach.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2019

memo - Magazine of European Medical Oncology 4/2019 Zur Ausgabe